Search
RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD
He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including...
May 21
Pravin Dugel on taking the job of executive chairman at Ocular Therapeutix
He describes what made him excited about the company, and why he views diabetic retinopathy as potentially a bigger opportunity than wet AMD
Feb 26, 2024
OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO
Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.
Jun 12, 2023
.png){kind=logo}
